Theradiag Reports Revenue of €5.5 Million for the First Half of 2021, Up 12.5%
July 19 2021 - 1:30AM
Business Wire
- H1 2021 revenue growth of 14.7 % for Theranostics
- Theranostics activity up 33.6% in the United States
- Good performance for IVD, with growth of 10.4%
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics and
Theranostics, today announces its half-year revenue and cash
position at June 30, 2021, data that is currently being
audited.
H1 2021 revenue of €5.5 million
In thousands of euros
June 30, 2021
June 30, 2020
Change
Revenue*
5,482
4,871
+12.5%
of which Theranostics revenue
2,766
2,410
+14.7%
of which IVD revenue
2,716
2,461
+10.4%
*Data currently being audited
Over the six months to June 30, 2021, Theradiag generated
revenue of €5.5 million, compared with €4.9 million in the first
half of 2020, giving growth of 12.5% despite an economic and public
health context characterized by persistent difficulties accessing
hospital treatment for patients undergoing immunotherapy in all
countries.
Theranostics activity continued its growth, increasing by
+14.7% in H1, notably driven by dynamic sales of the automated
i-Track10. Marked by strong growth for a number of semesters now,
for the first time Theranostics activity accounted for the majority
of Theradiag’s revenue over the first 6 months of 2021.
Theranostics activity undertaken in the United States in
partnership with HalioDX generated revenue of €0.5 million, in line
with the Company’s development plan, and was thus up by 33.6%. In
its export business, the Company has maintained a buoyant level of
activity, with sales increasing by 27.4% to €1.3 million. Penalized
by the maintaining of plans blancs emergency plans in hospitals,
activity in France slowed slightly, slipping 5.2% compared with the
first half of 2020 to €1.0 million.
IVD (In Vitro Diagnostics) activity generated growth of
+10.4%, with revenue totaling €2.7 million over the six months to
June 30, 2021.
Cash position
At June 30, 2021, Theradiag had €1.4 million in net available
cash, compared with €3.5 million at December 31, 2020. This
difference is the result of cash lags, now resolved, totaling €0.5
million, as well as investments in R&D and international
development, in line with Theradiag’s strategic plan.
Bertrand de Castelnau, Theradiag’s CEO, commented: “Our
revenue growth of 12.5% in a difficult public health context again
proves that Theradiag’s business model is based on solid
fundamentals. During the first half of 2021, our Theranostics
activity continued its growth thanks to the deployment of the
i-Track solution whose marketing was launched during the middle of
the lockdown in 2020. The particularly buoyant Theranostics
momentum in the United States highlights the success of our
partnership with Halio DX in that strategic country. The first half
was also marked by the launch of the Humabdiag project with the
University of Tours that will enable us to obtain high-quality
antibodies that are strategic for the Company’s future. During the
second half of 2021, we will maintain our investments in innovation
and our international deployment efforts, notably in the United
States”.
Pierre Morgon, Chairman of Theradiag’s Board of
Directors, added: “This first half of the year highlights the
robust nature of the model shaped over recent years by Theradiag’s
teams, who have illustrated their performance in a crisis. Global
leader in biotherapy monitoring, Theradiag has a real technological
lead that it is continuing to maintain thanks to a sound investment
policy. This positive dynamic is supported by a clear and ambitious
strategic plan that cannot fail to provide Theradiag with a bright
future”.
Reminder of the main H1 2021 highlights
- January 2021: CE marking for the four new i-Tracker® test kits,
i-Tracker® Vedolizumab, i-Tracker® Anti-Vedolizumab, i-Tracker®
Ustekinumab and i-Tracker® Anti-Ustekinumab on originator and
biosimilar molecules
- January 2021: Signing of a contract to supply Orgentec with
quality control reagents
- May 2021: Participation in Humabdiag, a large-scale research
project targeting the bioproduction of monoclonal antibodies in
Tours
Next financial press release:
- H1 2021 results, on Monday September 20, 2021
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210718005006/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Apr 2023 to Apr 2024